CNS Summit 2013, Boca Raton, FL Christopher Missling, Tangui Maurice, Athan Spiros, Patrick Roberts and Hugo Geerts View Poster Post navigationPreviousPrevious post:Anavex CEO Invited to Present at Upcoming Investment ConferencesNextNext post:Anavex Appoints Clinical Design Expert to Scientific Advisory BoardRelated PostsAnavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease DementiaJuly 9, 2018Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseJuly 3, 2018Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical HypertensionJanuary 16, 2018Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 ConferenceMay 22, 2017
Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease DementiaJuly 9, 2018
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseJuly 3, 2018
Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical HypertensionJanuary 16, 2018
Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 ConferenceMay 22, 2017
